HDM1005

Asset

Long-acting dual GLP-1 and GIP receptor agonist promoting weight loss and improving glycemic control.

Stage
Phase 2
Modality
Peptide
Target
GLP1R
1
Indication
0
Trials
1
Developer

Indications

1
  • Obesity

    Phase 2, doi.org, 5 Jun 2026

In the full profile

  • Targets and what it contains2
  • Owner and partners1
  • Evidence for its targets3
  • Competitors12
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets